DOCS - Ticker AI Digest

Dr. Martens PLC 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (DOCS) 1
DOCS 09:50
Dr. Martens PLC
Director/PDMR Shareholding
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 2
DOCS 09:50
Dr. Martens PLC
Director/PDMR Shareholding
DOCS 08:25
Dr. Martens PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
The SIP is an HMRC approved, all-employee scheme under which participating employees are able to <mark style="background-color:yellow">purchase</mark> shares in the Company from monthly salary (Partnership Shares) and receive allocations of free Matching Shares, awarded at a rate of one Matching Share for every one Partnership Share purchased by a participating employee, from the Company.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 1
DOCS 06:01
Dr. Martens PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 1
DOCS 06:01
Dr. Martens PLC
Q3 FY26 Trading Statement
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Dr. Martens PLC Q3 FY26 Trading Statement Summary**
Dr. Martens PLC released its Q3 FY26 trading statement on January 27, 2026, highlighting progress in executing its consumer-first strategy despite a challenging consumer environment. Key takeaways include
1. **Strategic Focus and Performance**
The company remains on track for significant profit growth in FY26, prioritizing revenue quality over volume by reducing promotions and clearance activity.
Full-price Direct-to-Consumer (DTC) revenues increased by 2% year-to-date (YTD), with strong performance in the Americas.
Group revenue declined 2.7% on a constant currency (CC) basis in Q3 to £253 million, with YTD revenue down 0.7% to £580 million CC.
2. **Regional Performance**
**Americas**Delivered 2% revenue growth in Q3, driven by 1% DTC growth and 6% wholesale growth (CC), resulting in 4.5% YTD growth.
**EMEA**Overall revenue declined 6% CC in Q3, with wholesale up 13% and DTC down 12% (CC), reflecting a challenging market and disciplined promotional approach.
**APAC**Wholesale revenue grew 8%, while DTC declined 6%, leading to a 3% overall revenue decline (CC), with strong growth in South Korea.
3. **Strategic Objectives**
Progress on all four growth leversreducing reliance on discounted pairs in Americas wholesale, driving growth in key product families (Buzz, Zebzag, Lowell), expanding into new markets via a capital-light structure, and simplifying the operating model.
Extended distribution agreement in Latin America to include Colombia, Costa Rica, Peru, and Uruguay.
4. **Outlook**
Expects FY26 revenue to be broadly flat on a constant currency basis, focusing on profitability and sustainable growth.
Comfortable with market expectations for significant year-on-year PBT growth, despite a £15 million currency headwind to Group revenue.
5. **Leadership and Brand**
CEO Ije Nwokorie emphasized the company’s commitment to its consumer-first strategy and thanked employees and partners for their dedication.
Dr. Martens continues to honor its heritage while expanding globally, operating in over 60 countries with a focus on craftsmanship and innovation.
The company remains confident in its strategic direction, prioritizing long-term growth and profitability despite near-term challenges.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 6
DOCS 09:50
Dr. Martens PLC
Director/PDMR Shareholding
DOCS 10:16
Dr. Martens PLC
Total Voting Rights
DOCS 06:01
Dr. Martens PLC
EBT Share Purchase
DOCS 06:01
Dr. Martens PLC
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
DOCS 06:01
Dr. Martens PLC
Q3 FY26 Trading Statement
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Dr. Martens PLC Q3 FY26 Trading Statement Summary**
Dr. Martens PLC released its Q3 FY26 trading statement on January 27, 2026, highlighting progress in executing its consumer-first strategy despite a challenging consumer environment. Key takeaways include
1. **Strategic Focus and Performance**
The company remains on track for significant profit growth in FY26, prioritizing revenue quality over volume by reducing promotions and clearance activity.
Full-price Direct-to-Consumer (DTC) revenues increased by 2% year-to-date (YTD), with strong performance in the Americas.
Group revenue declined 2.7% on a constant currency (CC) basis in Q3 to £253 million, with YTD revenue down 0.7% to £580 million CC.
2. **Regional Performance**
**Americas**Delivered 2% revenue growth in Q3, driven by 1% DTC growth and 6% wholesale growth (CC), resulting in 4.5% YTD growth.
**EMEA**Overall revenue declined 6% CC in Q3, with wholesale up 13% and DTC down 12% (CC), reflecting a challenging market and disciplined promotional approach.
**APAC**Wholesale revenue grew 8%, while DTC declined 6%, leading to a 3% overall revenue decline (CC), with strong growth in South Korea.
3. **Strategic Objectives**
Progress on all four growth leversreducing reliance on discounted pairs in Americas wholesale, driving growth in key product families (Buzz, Zebzag, Lowell), expanding into new markets via a capital-light structure, and simplifying the operating model.
Extended distribution agreement in Latin America to include Colombia, Costa Rica, Peru, and Uruguay.
4. **Outlook**
Expects FY26 revenue to be broadly flat on a constant currency basis, focusing on profitability and sustainable growth.
Comfortable with market expectations for significant year-on-year PBT growth, despite a £15 million currency headwind to Group revenue.
5. **Leadership and Brand**
CEO Ije Nwokorie emphasized the company’s commitment to its consumer-first strategy and thanked employees and partners for their dedication.
Dr. Martens continues to honor its heritage while expanding globally, operating in over 60 countries with a focus on craftsmanship and innovation.
The company remains confident in its strategic direction, prioritizing long-term growth and profitability despite near-term challenges.
DOCS 08:25
Dr. Martens PLC
Director/PDMR Shareholding
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
The SIP is an HMRC approved, all-employee scheme under which participating employees are able to <mark style="background-color:yellow">purchase</mark> shares in the Company from monthly salary (Partnership Shares) and receive allocations of free Matching Shares, awarded at a rate of one Matching Share for every one Partnership Share purchased by a participating employee, from the Company.

AI Crunch

Single-Ticker AI Crunch
DOCS signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Dr. Martens PLC. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full DOCS AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for DOCS on 2026-02-13.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
623545728
Enterprise Value
3005455882
Public Float
53.78
Broker Target
103.5
Shares Out
966737603
Long Interest
86
Short Interest
14
Exchange
LSE
Currency Code
GBX
ISIN
GB00BL6NGV24
Market
LSE - MAIN MARKET
Sector
Personal Goods
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
0.03
Ex Divi
2026-03-05
Earnings Date
2025-11-20
Net Debt
248200000.0
Cash
155900000.0
EPS
0.02
Net Income
4500000.0
Revenue
787600000.0
Enterprise Value
3005455882
Trailing PE
32.25
Forward PE
0.254
Price Sales TTM
0.7943
Price Book MRQ
1.9153
EV Revenue
1.1869
EV EBITDA
7.4537

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
20.426
Institutions As Of
2026-03-20
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
25
Sale Director Dealing
1
Purchase TR1
5
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
2
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit DOCS.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2026-02-13 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Dr. Martens PLC has fresh news flow feeding the chart narrative.
09:50 Today's Catalyst Director/PDMR Shareholding
AI Charts Studio
DOCS Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-02-13 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 6.31%
RSI Gauge
Price Change
AI Forecast